Concretely: a 25G drawing needle · 8 mg/mL.
Please show the division. I want to check my own against yours.
I would like the general form as well as the specific number, so I can apply it again.
How many significant figures are actually justified here?
At 8 mg/mL every microlitre left behind is 8 µg, so a 50 µL hub costs 0.4 mg per draw and a 5 µL fixed-needle barrel costs 0.04 mg. Multiply by the draws, not by the doses: ten draws through a 50 µL dead space is 4 mg gone, which at 8 mg/mL is 0.5 mL of solution you paid for and never administered. Against a 2 mg dose that 50 µL is 20 per cent; against a 0.25 mg dose it is 160 per cent, which is why the loss matters most at exactly the doses where you can least afford it. a 25G drawing needle has a bore, a hub and a length, and the hub dominates: a fixed-needle insulin barrel has almost none, a luer connection has a measurable one before the needle even starts.
The relevant detail is that the single most important fact about dead space is that it is almost entirely in the hub cone, not in the needle, which is why changing needle gauge or length barely changes your losses.
At 5 mg/mL that is 15 to 25 µg lost per draw on the insulin syringe and 175 to 500 µg on the luer-lock — which over ten draws is the difference between losing a rounding error and losing half a milligram.
| Configuration | Dead volume | Loss at 5 mg/mL | Over 20 draws |
|---|---|---|---|
| Fixed-needle insulin syringe | 3–5 µL | 15–25 µg | 0.3–0.5 mg |
| Low-dead-space, detachable | <2 µL | <10 µg | <0.2 mg |
| Standard luer-lock + 30G | 35–60 µL | 175–300 µg | 3.5–6 mg |
| Luer-lock + 21G drawing needle | 70–100 µL | 350–500 µg | 7–10 mg |
The luer cone of the syringe plus the needle's own plastic hub accounts for the vast majority of the dead space.
Published inter-laboratory comparisons of dead-space measurements on identical syringes show good agreement, suggesting the numbers are reliable.
One qualification: the dead space does not affect the dose accuracy if the hub was full of solution at the start of the draw.
The switch nearly doubles your vial, which is better than most other optimisations combined.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsWorth being precise here: this is arithmetic, so let us do the arithmetic and see where the losses actually are.
Low-dead-space syringe designs either have the needle bonded directly to the barrel — a fixed-needle syringe, which is the cheapest route — or add a moulded projection on the plunger tip that fills the luer cone.
Corollary that follows immediately: changing needle gauge or length barely changes your losses.
Syringe residual volume has been measured properly, mainly in the infection-control literature, with a median residual of about 84 µL for a conventional 1 mL syringe with a detachable needle and roughly 2 µL for a fixed-needle low-dead-space design.
Worth noting: draw size matters enormously — the smaller your draws, the more the syringe architecture matters.
Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.
On the detail: dead space is irreducible with a high-dead-space syringe, which is why the hardware matters more than any technique.
Be sceptical of anything advertised as low dead space that retains a conventional plunger tip: if you can look into the fitting with the plunger fully forward and see an open conical void, that void is your dead space.
Dead space quantified: a fixed-needle insulin syringe holds roughly 3 to 5 µL in the hub and needle after the plunger bottoms out. A luer-lock syringe with a detachable needle holds 35 to 100 µL depending on the hub design.
The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.
The limitation is that even with perfect technique, some loss is irreducible unless you switch to a low-dead-space syringe.
If cost matters, this is the first thing to change, not the last.
edited 26 Jun 2026 by v_ramaswamy — updated for the 2026 guidance change
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.